We Are Looking at Half the Picture
When a couple walks into a fertility clinic for the first time, the initial clinical focus
almost always centres on the woman. Her cycle, her ovarian reserve, her anatomy
her hormones. The male partner, meanwhile, is often handed a semen analysis
request form and asked to return in a few weeks.
This default is not intentional. It is a structural habit — one built over decades of
reproductive medicine that evolved around the female reproductive system simply
because it is more complex, more visible, and more directly tied to the pregnancy
itself.
But the data has been clear for a long time: male factor infertility contributes to
approximately 40–50% of all infertility cases, either as the sole cause or as a
contributing factor. And the clinical and emotional attention given to male patients
rarely reflects that figure.
The Sperm Quality Conversation We Are Not Having Loudly Enough
A landmark meta-analysis published in Human Reproduction Update in 2017 — and
updated in 2022 — reported a significant decline in sperm counts among men in
Western countries over a 40-year period. Subsequent analyses have extended that
picture globally. The trend is not disputed. What remains less clear is the full extent
of the causative factors.
Lifestyle contributors — obesity, heat exposure, smoking, alcohol, anabolic steroid
use — are well established. Environmental factors, including endocrine-disrupting
chemicals, are increasingly under scrutiny in the research literature. And
psychosocial stress, which sits at the intersection of the physical and the emotional,
is gaining attention as a meaningful variable in male reproductive health.
Yet in many fertility consultations, the lifestyle conversation with the male partner is
brief, generic, or absent. The opportunity to meaningfully intervene before treatment
begins is frequently missed.
Standard Testing Is Not Enough
A basic semen analysis — count, motility, morphology — remains the standard first-
line male investigation in most fertility pathways. And it is a useful starting point. But
it tells us surprisingly little about functional sperm quality.
Sperm DNA fragmentation index (DFI) is one of the most clinically relevant
underutilised investigations in reproductive medicine. Elevated DFI has been
associated with fertilisation failure, poor embryo development, increased miscarriage
risk, and reduced IVF success rates in multiple studies. It is not assessed in
standard semen analysis, and it is not routinely ordered in many clinical settings —
even for couples with a history of repeated implantation failure or unexplained
pregnancy loss.
The case for integrating sperm DNA fragmentation testing into standard fertility
investigation — particularly in couples with unexplained infertility or recurrent loss —
is supported by a growing evidence base. The question is why it remains exceptional
rather than routine.
The Human Cost of Being an Afterthought
Beyond the clinical, there is a human reality that the fertility industry often handles
poorly: the emotional experience of a male factor diagnosis.
For many men, the first conversation about their fertility is also the first time they
have ever been asked to consider their reproductive health at all. Cultural narratives
about masculinity are deeply intertwined with fertility in many communities — across
cultures, across continents. The shame that can accompany a diagnosis of severe
oligozoospermia, azoospermia, or high DNA fragmentation is often carried silently,
without acknowledgement, and without adequate psychological support.
Research consistently shows that men going through fertility treatment experience
clinically significant levels of anxiety and depression — often comparable to their
female partners — but are less likely to be offered psychological support, less likely
to access it when offered, and less likely to be screened for distress during the
clinical process.
Changing this requires more than adding a referral pathway. It requires the clinical
team to actively normalise the emotional dimension of male fertility — in how they
communicate, in how they structure consultations, and in how they follow up.
What Better Practice Looks Like
Leading fertility centres have moved toward concurrent investigation — evaluating
both partners simultaneously from the first appointment, rather than sequentially.
This is not only more efficient; it is more equitable, and it signals from the outset that
this is a shared journey.
Beyond investigation, better practice includes routine lifestyle counselling for male
partners, clear communication about the evidence base for antioxidant
supplementation and other male-directed interventions, and genuine integration of
psychological support into the male fertility pathway — not as an afterthought, but as
a standard component of care.
A Shared Journey Demands Equal Attention
Fertility treatment is not a female experience with a male bystander. It is a shared
experience, with two people carrying real emotional and physical stake.
The clinical pathways we build, the communication frameworks we use, and the
support structures we put in place should reflect that fully.
For those working in reproductive medicine: how has your practice evolved around
male factor investigation and support? And where do you still see the most
significant gaps?
